# The Safety and Pharmacokinetics of Carbavance™ (RPX2014/RPX7009) in Subjects With Renal Insufficiency

> **NCT02020434** · PHASE1 · COMPLETED · sponsor: **Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)** · enrollment: 32 (actual)

## Conditions studied

- Subjects With Varying Degrees of Renal Insufficiency and
- Subjects With Normal Renal Function

## Interventions

- **DRUG:** RPX7009 and RPX2014

## Key facts

- **NCT ID:** NCT02020434
- **Lead sponsor:** Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2014-09
- **Final completion:** 2014-10
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2018-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02020434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02020434, "The Safety and Pharmacokinetics of Carbavance™ (RPX2014/RPX7009) in Subjects With Renal Insufficiency". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02020434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*